Choline C-11
FDA-approved product (injectable, intravenous), marketed as Choline C-11.
- Registered studies
- 27
- Lab records
- 2
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Prostate adenocarcinoma
- Prostate cancer
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- FDA pharmacologic class
- Radioactive Diagnostic Agent FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Choline C-11, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA11.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli5.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae5.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis17.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
27registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 0 of 1 lab record
- E. coli: measured active in 0 of 1 lab record
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Choline C-11 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Diagnostic Performance of [11C]Choline PET/CT In the Preoperative Assessment of Primary Hyperparathyroidism
NCT06647966 · start 2025-01
Registered record
- Registry ID
- NCT06647966
- Conditions
- Primary Hyperparathyroidism
- Interventions
- PET/CT
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2025-01
- Completion
- 2025-12
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary HyperparathyroidismInterventionPET/CTPhaseNot recordedRegistry statusNot yet recruitingCharacterizing LAM With 11C-Choline PET/CT
NCT05087134 · start 2021-11
Registered record
- Registry ID
- NCT05087134
- Conditions
- Lymphangioleiomyomatosis
- Interventions
- 11C-Choline
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Unknown
- Start
- 2021-11
- Completion
- 2023-09
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphangioleiomyomatosisIntervention11C-CholinePhaseEarly phase 1Registry statusUnknown[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
NCT04693169 · start 2021-01-15
Registered record
- Registry ID
- NCT04693169
- Conditions
- Prostate Cancer
- Interventions
- 11C-Choline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-01-15
- Completion
- 2024-12-12
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerIntervention11C-CholinePhaseNot applicableRegistry statusUnknownPSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer
NCT04560725 · start 2020-10-22
Registered record
- Registry ID
- NCT04560725
- Conditions
- Prostate Cancer
- Interventions
- 11C-Choline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2020-10-22
- Completion
- 2024-12-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerIntervention11C-CholinePhaseNot applicableRegistry statusUnknownPSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
NCT03768349 · start 2019-01-03
Registered record
- Registry ID
- NCT03768349
- Conditions
- Prostate Cancer
- Interventions
- Ga-68 PSMA11; F-18 PSMA 1007
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2019-01-03
- Completion
- 2021-07-21
- Enrolment
- 250
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionGa-68 PSMA11; F-18 PSMA 1007PhaseEarly phase 1Registry statusCompletedStaging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
NCT03404648 · start 2017-11-01
Registered record
- Registry ID
- NCT03404648
- Conditions
- Prostate Adenocarcinoma
- Interventions
- C-11 choline PET tracer; Gadobutrol; PET/MR scanner
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-11-01
- Completion
- 2020-01-23
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate AdenocarcinomaInterventionC-11 choline PET tracer; Gadobutrol; PET/MR scannerPhasePhase 3Registry statusCompletedMolecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer
NCT03451812 · start 2017-01-01
Registered record
- Registry ID
- NCT03451812
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2017-01-01
- Completion
- 2019-12-31
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate AdenocarcinomaInterventionNot recordedPhaseNot recordedRegistry statusUnknownAssessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
NCT02849171 · start 2016-07
Registered record
- Registry ID
- NCT02849171
- Conditions
- Brain Cancer
- Interventions
- PET scan; C-Choline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2016-07
- Completion
- 2022-05-06
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBrain CancerInterventionPET scan; C-CholinePhaseNot applicableRegistry statusCompleted11C-choline PET/CT Based Helical Tomotherapy as Innovative Treratment Approach for Bone Metastases in Prostate Cancer Patients.
NCT06179706 · start 2015-10-27
Registered record
- Registry ID
- NCT06179706
- Conditions
- Prostate Cancer
- Interventions
- 11C-choline PET/CT
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-10-27
- Completion
- 2015-11-25
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerIntervention11C-choline PET/CTPhaseNot recordedRegistry statusCompletedRadiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?
NCT06170164 · start 2015-10-08
Registered record
- Registry ID
- NCT06170164
- Conditions
- Prostate Cancer
- Interventions
- Diagnostic accuracy
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-10-08
- Completion
- 2015-11-25
- Enrolment
- 68
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDiagnostic accuracyPhaseNot recordedRegistry statusCompletedCarbon-11 Labeled Sarcosine in Prostate Cancer
NCT02462447 · start 2015-06
Registered record
- Registry ID
- NCT02462447
- Conditions
- Prostate Cancer
- Interventions
- 11C-sarcosine; 11C-choline
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-06
- Completion
- 2017-02-08
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerIntervention11C-sarcosine; 11C-cholinePhaseNot recordedRegistry statusCompleted11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
NCT02397408 · start 2015-04-09
Registered record
- Registry ID
- NCT02397408
- Conditions
- Prostate Cancer
- Interventions
- Carbon C 11 Choline; Fluorine F 18 Choline; Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-04-09
- Completion
- 2015-06-30
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionCarbon C 11 Choline; Fluorine F 18 Choline; Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)PhasePhase 2Registry statusCompleted11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
NCT02519075 · start 2015-04
Registered record
- Registry ID
- NCT02519075
- Conditions
- Hepatocarcinoma
- Interventions
- No intervention
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-04
- Completion
- 2018-12
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatocarcinomaInterventionNo interventionPhaseNot recordedRegistry statusCompletedA Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT in Primary Hyperparathyroidism
NCT04608253 · start 2015-01-01
Registered record
- Registry ID
- NCT04608253
- Conditions
- Primary Hyperparathyroidism; Primary Hyperparathyroidism Due to Adenoma
- Interventions
- 11C-choline PET/CT
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-01-01
- Completion
- 2020-08-01
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary Hyperparathyroidism; Primary Hyperparathyroidism Due to AdenomaIntervention11C-choline PET/CTPhaseNot recordedRegistry statusCompletedThe Role of C-11 Choline PET in Patients With Prostate Cancer
NCT02852122 · start 2015-01
Registered record
- Registry ID
- NCT02852122
- Conditions
- Latent Cancer Prostate
- Interventions
- C-11 choline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2015-01
- Completion
- 2016-12
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLatent Cancer ProstateInterventionC-11 cholinePhaseNot applicableRegistry statusCompleted